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We would like to thank Dr. Thevenot et al. for their interest in our
study on the effect of albumin administration in patients with
cirrhosis and infections other than spontaneous bacterial perito-
nitis [1]. Our answers to their comments are as follows: (1) the
statistical difference between the per-protocol analysis and
intention-to-treat analysis is minimal, as indicated by their corre-
sponding hazard ratios (0.29 and 0.35, respectively) and p values
(0.042 and 0.06), despite the fact that the latter falls outside the
level of signiﬁcance. Therefore, no relevant conclusions can be
made with respect to this slight difference; (2) the statement that
progressive kidney failure occurs only in subdiaphragmatic infec-
tions is not in agreement with our experience. We agree with the
authors of the letter that it would have been important to include
patients without SBP with high risk of kidney failure; however,
this information was not available when we started the study
and is still insufﬁcient today; (3) we agree that our assumption
of a beneﬁcial effect of albumin was over-optimistic, but our
results indicate that any study aimed at investigating the effects
of albumin in this patient population must include a very large
sample size; (4) as indicated in the statistical section of our paper,
the purpose of the multivariate model was not to select the best
subset of variables predicting survival, but to assess the effect of
treatment with albumin after adjusting for potential confounders
in an explanatory model. The 1:10 rule is a good one when the
statistical signiﬁcance of variables to be included in the model
is relevant. In our case, the main interest was to estimate the risk
reduction associated with the albumin treatment in the most
accurate way. Assessment of potential confounders is based on
the magnitude of changes in the treatment coefﬁcient and not
on the statistical signiﬁcance of confounders; (5) the beneﬁcial
effect of albumin on systemic hemodynamics was crystal clear
and is consistent with the effects of albumin observed on sys-
temic hemodynamics in patients with SBP [2,3]. The effect of
albumin treatment on the activity of vasoconstrictor systemsJournal of Hepatology 20was analyzed in almost half of the patients included, which is a
high percentage considering the logistical difﬁculties in studies
involving these types of patients. Finally, we believe that our
study has set the stage for investigating the effects of albumin
in patients with cirrhosis and sepsis (without SBP) and we are
conﬁdent that more randomized studies will be performed in this
important ﬁeld. The results of these studies are eagerly awaited.
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